Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAB Biotherapeutics (SABS)
NASDAQ:SABS
RESEARCH TOOLSreports
Holding SABS?
Track your performance easily
SABS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.16 - $9.72
Previous Close$3.19
Volume21.64K
Average Volume (3M)64.89K
Market Cap
$29.44M
Enterprise Value$3.56M
Total Cash (Recent Filing)$30.40M
Total Debt (Recent Filing)$4.52M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
May 08, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.31
Shares Outstanding9,229,274
10 Day Avg. Volume96,485
30 Day Avg. Volume64,891
Standard Deviation0.29
R-Squared0.02
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.80
Price to Sales (P/S)11.30
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.95
Enterprise Value/Gross Profit1.59
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$13.50Price Target Upside294.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
SAB Biotherapeutics News
PremiumCompany Announcements
SAB Biotherapeutics Advances in Type 1 Diabetes Immunotherapy Trial
PremiumCompany Announcements
SAB Biotherapeutics Announces Key Executive AppointmentRisk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SABS FAQ
What was SAB Biotherapeutics’s price range in the past 12 months?
SAB Biotherapeutics lowest stock price was $2.16 and its highest was $9.72 in the past 12 months.
What is SAB Biotherapeutics’s market cap?
Currently, no data Available
When is SAB Biotherapeutics’s upcoming earnings report date?
SAB Biotherapeutics’s upcoming earnings report date is May 08, 2025 which is in 168 days.
How were SAB Biotherapeutics’s earnings last quarter?
SAB Biotherapeutics released its earnings results on Nov 06, 2024. The company reported -$1.12 earnings per share for the quarter, missing the consensus estimate of -$1.106 by -$0.014.
Is SAB Biotherapeutics overvalued?
According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued.
Does SAB Biotherapeutics pay dividends?
SAB Biotherapeutics does not currently pay dividends.
What is SAB Biotherapeutics’s EPS estimate?
SAB Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SAB Biotherapeutics have?
SAB Biotherapeutics has 9,229,274 shares outstanding.
What happened to SAB Biotherapeutics’s price movement after its last earnings report?
SAB Biotherapeutics reported an EPS of -$1.12 in its last earnings report, missing expectations of -$1.106. Following the earnings report the stock price went down -17.215%.
Which hedge fund is a major shareholder of SAB Biotherapeutics?
Among the largest hedge funds holding SAB Biotherapeutics’s share is RA Capital Management. It holds SAB Biotherapeutics’s shares valued at N/A.
---
SAB Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (294.74% Upside)
$13.50 (294.74% Upside)
Hedge Fund Trend
Decreased
By 237.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.12%
12-Months-Change
Fundamentals
Return on Equity
-174.73%
Trailing 12-Months
Asset Growth
89.85%
Trailing 12-Months
Company Description
SAB Biotherapeutics
Blue Calypso Inc is engaged in the development, sales, delivery and licensing of technology and intellectual property focused on mobile shopper engagement, digital word of mouth and location-based marketing and advertising. Its solutions include mobile engagement, POP and merchandise tracking, mobile plant tag engagement. The company derives its revenues from the cloud-based consumption of its technology platform, consulting fees and licensing of its technologies.
---
SABS Stock 12 Month Forecast
Average Price Target
$13.50
▲(294.74% Upside)
Technical Analysis
Best Analysts Covering SABS
1 Year
1 Year Success Rate
2/13 ratings generated profit
1 Year Average Return
-29.18%
reiterated a buy rating 15 days ago
Copying Edward White's trades and holding each position for 1 Year would result in 15.38% of your transactions generating a profit, with an average return of -29.18% per trade.
---